Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Nicox SA (NICXF : OTC)

• Company Description    Nicox S.A. is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. By leveraging their proprietary expertise in nitric oxide (NO) donation and other technologies, they are developing an extensive portfolio of novel product candidates that target multiple ophthalmic conditions, including glaucoma. Their portfolio includes three programs in development including NCX 470 for intraocular pressure lowering, based on their proprietary NO-donating research platform and NCX 4251, a proprietary formulation of the well-established molecule fluticasone, for acute exacerbations of blepharitis. Their research activities are focused on novel future generation NO-donors including NO-donating phosphodiesterase-5 (PDE5) inhibitors and NO-donating soluble guanylate cyclase (sGC) stimulators (in partnership with Ironwood). Number of Employees:

• Price / Volume Information    Yesterday's Closing Price: $0.30 Daily Weekly Monthly 20 Day Moving Average: 400 shares Shares Outstanding: 68.92 (millions) Market Capitalization: $20.67 (millions) Beta: 0.29 52 Week High: $0.30 52 Week Low: $0.24 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 20.00% 13.97% 12 Week 20.00% 4.52% Year To Date 25.00% 16.75%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL Drakkar 2 - Batiment D 2405 route des Dolines - CS 10313 Sophia Antipolis Cedex - Valbonne,I0 06560 FRA ph: 33-4-97-24-53-00 fax: 33-4-97-24-53-99 None http://www.nicox.com

• General Corporate Information    Officers Andreas Segerros - Chief Executive Officer and Chairman Jean-Francois Labbe - Chairman of the Board Sandrine Gestin - Vice President; Finances Michele Garufi - Director Emmanuelle Pierry - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: F6533F301 SIC: 8880 Fiscal Year Fiscal Year End: December Last Reported Quarter: - Next Expected EPS Date: - Share - Related Items Shares Outstanding: 68.92 Most Recent Split Date: 12.00 (0.20:1) Beta: 0.29 Market Capitalization: $20.67 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: -

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - - 12/31/24 - - ROA 06/30/25 - - 03/31/25 - - 12/31/24 - - Current Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - - Quick Ratio 06/30/25 - - 03/31/25 - - 12/31/24 - - Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - - 12/31/24 - - Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Capital 06/30/25 - - 03/31/25 - - 12/31/24 - -

Powered by Zacks Investment Research ©